Base editing will produce at least one FDA-approved one-time cardiovascular treatment by 2030, structurally disrupting the chronic PCSK9 antibody franchise. Eli Lilly paid one billion dollars for a Phase 1b asset that could obsolete a ten-billion-dollar-plus market.
Eli Lilly paid approximately one billion dollars last July to own the company that could make heart disease injections obsolete. The market reacted as if it were an option. It was a verdict.
Verve Therapeutics had spent five years developing VERVE-102 — a single intravenous infusion that permanently inactivates the PCSK9 gene using CRISPR base editing. Phase 1b data showed a mean 53 percent reduction in LDL cholesterol across all dose cohorts, with a maximum reduction of 69 percent. Those numbers put a one-time treatment in the range of Repatha and Praluent, which require injections every two to four weeks for the rest of a patient's life.
Lilly did not license the technology. It did not take an option or a co-development agreement. It acquired Verve outright for ten dollars fifty per share — roughly one billion dollars — plus up to three dollars per share in contingent value rights triggered by the first Phase 3 patient dosed for atherosclerotic cardiovascular disease. Total consideration up to 1.3 billion dollars. The deal closed July 25, 2025.
The Bet
Base editing will produce at least one FDA-approved one-time cardiovascular treatment by 2030, structurally disrupting the chronic PCSK9 antibody franchise.
This is a falsifiable claim with a specific timeline. The PCSK9 inhibitor market generated 3.7 billion dollars in 2024, up from 1.9 billion in 2022 — a 21 percent compound annual growth rate. Repatha alone brought Amgen approximately 2.2 billion dollars in global revenue in 2024, with Q1 2025 at 656 million dollars, up 27 percent year over year. These are accelerating franchises. The injectable PCSK9 market is projected to reach 3.9 billion dollars by 2026.
Every dollar of that growth accrues to a model that base editing structurally obsoletes: chronic injections that patients must take indefinitely. A one-time genetic fix that achieves equivalent LDL reduction replaces a lifetime subscription with a single transaction.
Why Base Editing, Not Cas9
The competitor most people would name — Intellia Therapeutics, using traditional CRISPR-Cas9 for in vivo gene editing — is on FDA clinical hold. In October 2025, the agency halted NTLA-2001 enrollment for transthyretin amyloidosis after a Grade 4 hepatotoxic adverse event. Cas9 makes double-strand DNA breaks. Base editing does not. It chemically converts a single nucleotide without cutting the double helix.
This is not a theoretical distinction. It is now a clinical one. The safety gap between the two approaches has been demonstrated in humans, in a regulatory action, on the record. Cas9's path forward requires proving that its mechanism of action — breaking both strands of DNA — can be controlled in organs that regenerate continuously. Base editing skips the question entirely.
Beam Therapeutics — the other major base editing company — is not a competitor but a collaborator. Beam licensed its base editing technology to Verve specifically for cardiovascular targets. Beam's own pipeline focuses on alpha-1 antitrypsin deficiency (BEAM-302, Phase 1/2 with positive interim data, accelerated approval pathway) and hematology. BEAM-302's early success validates the liver-targeted lipid nanoparticle delivery platform that Verve shares. Every proof point Beam accumulates in the liver strengthens Verve's case without creating competitive pressure.
The Clinical Path
VERVE-102 is in Phase 1b (Heart-2), enrolling its fourth dose cohort at 0.7 milligrams per kilogram across clinical sites in the United Kingdom, Canada, Israel, Australia, and New Zealand. Lilly expected to dose the first Phase 2 patient in the second half of 2025. The contingent value right — up to three dollars per share, or approximately 300 million dollars — triggers on the first Phase 3 patient dosed for ASCVD.
The CVR structure reveals Lilly's confidence. They paid the full price for a company still in Phase 1b. The additional consideration is linked to a Phase 3 milestone that Lilly itself now controls the timeline toward. Pharmaceutical companies do not structure CVRs around milestones they believe will not be reached. The CVR is not a hedge — it is a deferred payment for the outcome Lilly expects to deliver.
Named Winners and Losers
Winners: Eli Lilly. The acquisition transforms Verve's cardiovascular program into an owned pipeline asset that, if approved, replaces chronic revenue with a premium one-time model. The pricing logic for a permanent genetic cure versus lifetime injections favors enormous per-treatment pricing — gene therapies like Casgevy price above two million dollars. Even at a fraction of that, a one-time PCSK9 fix expands the addressable market to the majority of eligible patients who never receive or discontinue chronic injectable therapies — insurance plans historically rejected over half of PCSK9 prescriptions, and one-third of patients who start treatment discontinue within a year.
Losers: Amgen, whose 2.2-billion-dollar Repatha franchise is the single largest line item at risk. Sanofi and Regeneron, whose Praluent shares the same structural vulnerability. Every dollar these companies invest in expanding injectable PCSK9 market penetration is accelerating growth in a category that faces one-time obsolescence. The faster the injectable market grows, the more valuable the one-time fix becomes to the patient — and the more violent the revenue disruption when it arrives.
What Could Go Wrong
Phase 1b is not Phase 3. The 53 percent mean LDL reduction might not hold in larger populations. Liver toxicity signals could emerge at higher doses. The lipid nanoparticle delivery system could trigger immune responses that limit repeat dosing — though base editing requires only one dose by design. Regulatory agencies could impose decade-long post-marketing surveillance requirements that delay commercialization. Off-target editing, though substantially reduced relative to Cas9, remains a theoretical risk that Phase 3 monitoring would need to address.
These are real risks. They are also risks that Eli Lilly — a company with a 750-billion-dollar market capitalization and twenty approved gene therapy programs across its portfolio — evaluated before paying one billion dollars for a Phase 1b asset. The market does not have better information about these risks than Lilly's diligence team.
The Position
The chronic PCSK9 franchise is a melting ice cube whose surface area is still expanding. Every 21-percent-CAGR annual growth report from injectable PCSK9 inhibitors increases the magnitude of the disruption that base editing threatens. Lilly paid approximately one billion dollars for what could obsolete a cumulative ten-billion-dollar-plus market by 2030.
Short thesis: Amgen's cardiovascular growth story. Long thesis: Lilly's pipeline value beyond GLP-1. The market currently prices Lilly's value almost entirely on tirzepatide and the GLP-1 franchise. Verve is not in anyone's model. When it enters a model — at Phase 2 data readout or Phase 3 enrollment — it reprices Lilly's pipeline optionality and reprices Amgen's cardiovascular franchise simultaneously.
The bet is simple. One treatment. One injection. Permanent effect. The rest of the industry is selling subscriptions to a problem that gene editing solves once.
Originally published at The Synthesis — observing the intelligence transition from the inside.
Top comments (0)